We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Vicotex

Download Mobile App




Researchers Quantify the Uptake and Distribution of Targeted Nanoparticles

By LabMedica International staff writers
Posted on 23 Dec 2009
Nanoparticles linked to targeting molecules are increasingly being cited as potential chemotherapeutic agents, and a recent publication has now quantified how such molecules are distributed to various organelles within a target cell.

Investigators at Purdue University (West Lafayette, IN, USA) worked with nanorods constructed of gold and a magnetic material and coated with trastuzumab, an anticancer drug used to used to treat breast cancer that has metastasized in women whose tumor cells produce an overabundance of human epidermal growth factor receptor 2 (HER2). More...
The location of the nanorods in cultured breast cancer cells was determined by a combination of magnetic resonance spectrometry and microscopy. In some experiments, the drug was marked with a fluorescent molecule, and localization was quantified and diffusion times evaluated in different cell organelles by using fluorescence correlation spectroscopy (FCS).

Results published in the November 5, 2009, online edition of the journal ACS Nano revealed that, that in treated breast cancer cells the conjugated nanoparticles co-localized with the endosome and lysosome but not with the Golgi apparatus. The nanorods had similar intracellular localization characteristics as the fluorescently labeled drug. These findings not only lay the foundations for a quantitative understanding of the fate of nanoparticle-based targeting but also provide new insights into the rational design of nanoparticle delivery systems for effective treatment.

"Each nanoparticle acts like a deliverer of a mail package, or dose, of the drug directly to the appropriate location," said senior author Dr. Joseph Irudayaraj, professor of biological engineering at Purdue University. "We have demonstrated the ability to track these nanoparticles in different cellular compartments of live cells and show where they collect quantitatively. Our methods will allow us to calculate the quantities of a drug needed to treat a cancer cell because now we know how these nanoparticles are being distributed to different parts of the cell."

Related Links:
Purdue University



Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
New
Gold Member
POC Helicobacter Pylori Test Kit
Hepy Urease Test
New
Gold Member
Pre- Eclampsia Control
Acusera Pre-Eclampsia Control
Japanese Encephalitis Test
Japanese Encephalitis Virus Real Time PCR Kit
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: Researchers developed three mathematical biomarkers from routine PSA blood tests that may help predict early prostate cancer treatment outcomes and personalize adaptive therapy (Image Credit: Adobe Stock)

Mathematical Biomarkers Use Routine Blood Tests to Guide Adaptive Prostate Cancer Therapy

Personalizing systemic therapy for prostate cancer remains challenging because tumors can evolve under treatment pressure, driving resistance and early relapse. Continuous high-dose regimens may initially... Read more

Molecular Diagnostics

view channel
Image: The duet mosaic family comprises duet +modC mosaic and duet 6-base mosaic, two cfDNA-optimized multiomic sequencing workflows for liquid biopsy and translational research. (Photo courtesy of bimodal)

New Liquid Biopsy Workflow Maximizes Tumor Signals from Limited Blood Samples

Liquid biopsy seeks to detect tumor-derived signals from small blood samples, but circulating cell-free DNA is scarce and heterogeneous, limiting sensitivity. Combining complementary signals such as methylation,... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.